

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Vigonvita Life Sciences Co., Ltd.

蘇州旺山旺水生物醫藥股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2630)

ANNOUNCEMENT

PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Vigonvita Life Sciences Co., Ltd. (the **“Company”**) pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the **“Stock Exchange”**) (**“Listing Rules”**), in relation to the proposed amendments to the articles of association of Company (the **“Articles of Association”**).

The board (the **“Board”**) of directors (the **“Directors”**) of the Company announces that, in view of (i) upon completion of the issuance and listing of the Company's H shares on the Main Board of the Stock Exchange on November 6, 2025, in order to reflect the relevant changes in the Company's registered capital after listing, and (ii) the Company's business needs, the Company proposes to make amendments to the Articles of Association and complete the filing of the relevant amendments to the Articles of Association.

In view of the above, the Board proposed to make the following amendments to the Articles of Association:

Article No.	Existing Provisions of the Articles of Association	Amended Provisions of the Articles of Association
Article 6	Prior to the initial public offering of H Shares, the registered capital of the Company was RMB150,000,000.	Prior to After the initial public offering of H Shares, the registered capital of the Company was RMB150,000,000 167,597,800 .

Article No.	Existing Provisions of the Articles of Association	Amended Provisions of the Articles of Association
Article 10	Upon approval by a resolution of the Company's shareholders' meeting held on January 24, 2025, the Articles of Association shall become effective upon the listing and trading of the Company's H Shares on the Hong Kong Stock Exchange. Commencing from the date the Articles of Association take effect, the Articles of Association shall replace the articles of association of the Company previously registered with the companies registration authority. Commencing from the date the Articles of Association take effect, the Articles of Association will become a legally binding document that regulates the organization and conduct of the Company, as well as the rights and obligations between the Company and each shareholder and among the shareholders inter se. According to the Articles of Association, any shareholder may bring a lawsuit against another shareholder, a director, a supervisor, a manager or a senior management member of the Company, any shareholder may bring a lawsuit against the Company, and the Company may bring a lawsuit against any shareholder, director, supervisor or senior management member.	Upon approval by a resolution of the Company's shareholders' meeting held on January 24, 2025, the Articles of Association shall become effective upon the listing and trading of the Company's H Shares on the Hong Kong Stock Exchange. Commencing from the date the Articles of Association take effect, the Articles of Association shall replace the articles of association of the Company previously registered with the companies registration authority. Commencing from the date the Articles of Association take effect, the Articles of Association will become a legally binding document that regulates the organization and conduct of the Company, as well as the rights and obligations between the Company and each shareholder and among the shareholders inter se. According to the Articles of Association, any shareholder may bring a lawsuit against another shareholder, a director, a supervisor, a manager or a senior management member of the Company, any shareholder may bring a lawsuit against the Company, and the Company may bring a lawsuit against any shareholder, director, supervisor or senior management member.

Article No.	Existing Provisions of the Articles of Association	Amended Provisions of the Articles of Association
Article 14	The Company's business scope, as registered by law, is: Licensed items: Pharmaceutical manufacturing; contract manufacturing of drugs; wholesale of pharmaceuticals; manufacturing of health food; sales of health food; import and export of pharmaceuticals (For items subject to approval according to law, relevant business activities shall be carried out only after approval of relevant departments. Specific business items are subject to the approval results) General items: Medical research and experimental development; cell technology research and development and application; biochemical product technology research and development; sales of specialty chemicals (excluding hazardous chemicals); technical services, technical development, technical consulting, technical exchange, technology transfer, and technology promotion; import and export of technology (Except for items that require approval in accordance with the law, the Company may independently conduct business activities in accordance with the law based on its business license). The business scope referred to in the preceding paragraph shall be subject to registration with the companies registration authority.	The Company's business scope, as registered by law, is: Licensed items: Pharmaceutical manufacturing; contract manufacturing of drugs; wholesale of pharmaceuticals; manufacturing of health food; sales of health food; import and export of pharmaceuticals (For items subject to approval according to law, relevant business activities shall be carried out only after approval of relevant departments. Specific business items are subject to the approval results) General items: Medical research and experimental development; cell technology research and development and application; biochemical product technology research and development; sales of specialty chemicals (excluding hazardous chemicals); technical services, technical development, technical consulting, technical exchange, technology transfer, and technology promotion; import and export of technology (Except for items that require approval in accordance with the law, the Company may independently conduct business activities in accordance with the law based on its business license). The business scope referred to in the preceding paragraph shall be subject to registration with the companies registration authority.

Article No.	Existing Provisions of the Articles of Association	Amended Provisions of the Articles of Association
Article 109	The Board shall comprise between 6 and 19 directors, and shall have one chairman. The chairman shall be elected by a simple majority of all directors on the Board. The Board shall include at least three independent non-executive directors, at least one of whom must possess appropriate professional qualifications, or accounting or related financial-management expertise. At least one independent non-executive director must ordinarily reside in Hong Kong.	The Board shall comprise between 6 and 19 directors, and shall have one chairman. The chairman shall be elected by a simple majority of all directors on the Board. The Board shall include at least three independent non-executive directors, at least one of whom must possess appropriate professional qualifications, or accounting or related financial-management expertise. At least one independent non-executive director must ordinarily reside in Hong Kong.

Save for disclosed above, the contents of other provisions of the Articles of Association remain unchanged. The proposed amendments to the Articles of Association are subject to the consideration and approval of the shareholders of the Company (the “**Shareholders**”) by way of a special resolution at the forthcoming extraordinary general meeting (the “**EGM**”) of the Company. The existing Articles of Association remain effective before the passing of the relevant resolution at the EGM. A circular containing, among other things, details in respect of the proposed amendments to the Articles of Association, together with the notice of the EGM and the related proxy form, will be sent to the Shareholders in due course in accordance with the relevant provisions of the Listing Rules and the Articles of Association. As no Shareholder has a material interest in the proposed amendment of the Articles of Association, no Shareholder is required to abstain from voting on the resolution proposed to consider and approve the proposed amendments of the Articles of Association.

The Company will make further announcement(s) to inform the Shareholders of the results of the EGM and the effective date of the proposed adoption of the amended Articles of Association.

By order of the Board
Vigonvita Life Sciences Co., Ltd.
Dr. Tian Guanghui
*Chairman of the Board, Executive Director,
Chief Executive Officer and General Manager*

Hong Kong, March 31, 2026

As at the date of this announcement, the Board comprises Dr. Tian Guanghui and Dr. Hu Tianwen as executive Directors, Mr. Liu Haoxuan as non-executive Director, and Dr. Ju Dianwen, Ms. Cao Xinwen and Dr. Xu Hongxi as independent non-executive Directors.